Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 158, doi. 10.1007/s11899-023-00707-6
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2023 AND VI 18 AND IP 5
Results: 8
1
2
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 121, doi. 10.1007/s11899-023-00699-3
- By:
- Publication type:
- Article
3
Multiple Myeloma: Current Clinical Landscape and Compounding Costs.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 201, doi. 10.1007/s11899-023-00705-8
- By:
- Publication type:
- Article
4
Real-world Management of CML: Outcomes and Treatment Patterns.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 167, doi. 10.1007/s11899-023-00703-w
- By:
- Publication type:
- Article
5
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 176, doi. 10.1007/s11899-023-00702-x
- By:
- Publication type:
- Article
6
Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 144, doi. 10.1007/s11899-023-00701-y
- By:
- Publication type:
- Article
7
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 130, doi. 10.1007/s11899-023-00700-z
- By:
- Publication type:
- Article
8
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 190, doi. 10.1007/s11899-023-00704-9
- By:
- Publication type:
- Article